Study Group: Neurologists who Treat Alzheimer's Disease (US)(?)
Council Members in this Study Group: 203
Request a survey with this Study Group
Leading Experts in this Study Group
Daniel Wynn, MD
Director, Clinical Research
Consultants In Neurology Ltd.
Daniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple sclerosis, Alzheimer's disease, stroke, chronic...
Neurologist
Medford Neurological Clinic, Inc.
Walter Carlini, MD, PhD, is a General Neurologist at Medford Neurological Clinic in Oregon. His clinical interests include stroke, epilepsy, migraine, dementia, movement disorders, and multiple sclerosis. Dr. Carlini has expertise in clinical neurophysiology and in the use of botulinum toxin injections...
Josef Parvizi, MDAttending Neurologist
Stanford University Medical Center
Josef Parvizi, MD, PhD, is an Assistant Professor of Neurological Sciences at Stanford University. Dr. Parvizi has main interest in analyzing the design and results of new clinical trials, of medications or devices, in various fields of neurology. He has clinical expertise in Alzheimer's disease, neuropathic...
Professor of Neurology and Epidemiology
Boston University School of Medicine - CC
Robert C. Green, MD, MPH, is Professor of Neurology at Boston University School of Medicine (BUSM) and Professor of Epidemiology at Boston University School of Public Health. He is Co-Director of the Memory Assessment Clinics at Boston Medical Center, Associate Director and Clinical Core Leader of the...
Related Study Groups
| Study Group Name | Members |
|---|---|
| Neurologists (US) | 1086 |
| Neurologists | 1823 |
| Neurologists who Treat Epilepsy (US) | 333 |
| Attending-Level Neurologists at Academic Medical Centers (US) | 551 |
| Neurologists who Treat Neuromuscular Disorders (US) | 245 |
| Movement Disorder Neurologists (US) | 138 |
| Vascular Neurologists (US) | 162 |
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
The CONNECTION study is important in that Dimebon has a mode of action different from all other current treatments. If the results of the phase II study are corroborated, Dimebon may be an important, additional treatment modality.
Abuse resistant long acting narcotics offer benefit as they are less desirable to those who might wish a quick high via snorting, injecting crushed time-release narcotic. Unfortunately, given the higher cost than long acting generics and increased pressure on physicians to prescribe generics, expect...
I do not believe that any conclusions can be drawn from these data unless they can be confirmed by a larger, more wide ranging population sampling.
Vimpat was developed to have applicability to other disease processes including neuropathic pain. The limited indication approved for Vimpat suggests the data for other potential uses was not very robust (that had been my observation based on the neuropathic pain studies). Although UCB may be developing...
FDA has approved lacosamide for add-on therapy of partial onset seizures. It will be marketed by UCB under the brand name Vimpat.
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Academic Institution*
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Owner
- Physician - Division Head
- President
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms